The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: Does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

BJU International

Volumn 106, Issue 8, 2010, Pages 1143-1147

  Ploussard, Guillaume ^a   Haese, Alexander ^b   Van Poppel, Hendrik ^e   Marberger, Michael ^f   Stenzl, Arnulf ^d   Mulders, Peter F A ^g   Huland, Hartwig ^c   Bastien, Laurence ^a   Abbou, Clèment Claude ^a   Remzi, Mesut ^f   Tinzl, Martina ^f   Feyerabend, Susan ^d   Stillebroer, Alexander B ^g   Van Gils, Martijn P M Q ^g   Schalken, Jack A ^g   De La Taille, Alexandre ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b Department of Urology ^*  (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF VIENNA   (Austria)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biopsy; detection rate; PCA3; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TUMOR GENE; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957601351     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09286.x     Document Type: Article

References (21)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 18 : 581 92
2. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002 167 : 2435 9
3. Heidenreich A, Aus G, Bolla M et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80
4. Landers KA, Burger MJ, Tebay MA et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005 114 : 950 6
5. Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection. J Urol 2007 178 : 2252 9
6. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999 59 : 5975 9
7. Chun FK, de la Taille A, van Poppel H et al. Prostate cancer gene3 (PCA3). Development and internal validation of a novel biopsy nomogram. Eur Urol 2009 56 : 659 67
8. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009 6 : 255 61
9. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009 181 : 2508 13
10. Haese A, de la Taille A, van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008 54 : 1081 8
11. Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007 69 : 532 5
12. Deras IL, Aubin SM, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008 179 : 1587 92
13. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006 52 : 1089 95
14. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007 13 : 5103 8
15. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009 73 : 363 8
16. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 279 : 1542 7
17. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6-4.0 ng.ml. range. J Urol 2002 168 : 922 5
18. Djavan B, Zlotta A, Remzi M et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of1,051 men. J Urol 2000 163 : 1144 8
19. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 74
20. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008 179 : 1804 9
21. Whitman EJ, Groskopf J, Ali A et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor. J Urol 2008 180 : 1975 8